Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab plus prednisone vs placebo plus prednisone in giant cell arteritis
2015-001758-14Phase 3Terminated
- Sponsor
- GSK
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in giant cell arteritis (GCA) and vasculitis comparing Sirukumab + prednisone with Placebo + prednisone (2 arms). Primary endpoint: Sustained remission at Week 52. Started Jul 2015; status: terminated.
02
Drugs
sirukumab
03
Conditions
giant cell arteritis (GCA)vasculitis
Beyond the preview
Go deeper on 2015-001758-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001758-14.